24/7 Market News Snapshot 06 March, 2025 – Clearside Biomedical, Inc. Common Stock (NASDAQ:CLSD)

March 6, 2025

DENVER, Colo., 06 March, 2025 (247marketnews.com) – (NASDAQ:CLSD) are discussed in this article.
Clearside Biomedical, Inc. is experiencing notable market movement, currently trading at $1.005 with a substantial gain of 18.22% following an open of $0.88. This surge, supported by a trading volume of 949.26K, reflects increased investor interest and a potentially bullish outlook for the company. The positive market sentiment may stem from recent advancements in Clearside’s therapeutic pipeline, particularly regarding wet age-related macular degeneration (wet AMD) treatments. Investors are advised to watch key resistance levels and stay informed about developments that could impact price dynamics, as ongoing volume remains crucial to sustaining this upward momentum.

In a significant development, Clearside announced progress on CLS-AX, an injectable suspension of axitinib aimed at treating wet AMD. After a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), the company is set to initiate a Phase 3 clinical program to evaluate the treatment’s commercial viability. CLS-AX’s innovative delivery method, using the patented SCS Microinjector®, allows for biologic dosing with the extended duration typical of tyrosine kinase inhibitors, positioning it as a potential game-changer in the $12 billion AMD market.

The upcoming Phase 3 trials will incorporate two non-inferiority studies that assess CLS-AX’s effectiveness among a broad patient demographic. These trials are designed to adapt to individual treatment schedules, emphasizing Clearside’s focus on personalized medicine. The trials aim to compare CLS-AX against existing therapies, providing vital insights into its safety and efficacy.

Leveraging its targeted delivery system, Clearside seeks to offer sustained treatment effects while minimizing side effects. Previous clinical trials have indicated favorable results and tolerability, paving the way for further advancements in retinal disease therapeutics. Clearside remains committed to transforming treatment modalities, with discussions on the new Phase 3 program anticipated in the upcoming earnings call.

Related news for (CLSD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.